Germany's Public Health Chief Warns GLP-1 Coverage Could Cost GKV Billions as Obesity Drug Debate Intensifies

The Quick Take

• AOK Bundesverbandschefin Carola Reimann warned that covering weight-loss injections could cost German public health insurance (GKV) billions in extreme scenarios
• If all GKV-insured adults with obesity received treatment, costs could surge to unprecedented levels for the statutory system
• Debate over GKV coverage of GLP-1 drugs puts Germany on a similar policy path to other European markets weighing obesity drug benefits

AOK chief Carola Reimann has sounded a public warning that extending statutory health insurance (GKV) coverage to weight-loss injections — including GLP-1 receptor agonists like semaglutide — could burden Germany's public health system with multi-billion-euro costs in extreme scenarios. The warning comes as European health systems grapple with whether the long-term benefits of obesity drug treatment justify the near-term premium cost per patient, which in Germany's GKV context means costs are socialised across all premium payers rather than borne by private insurers.

Pharmaceutical sector implications are substantial: a German GKV coverage approval would dramatically expand the addressable market for GLP-1 manufacturers, including Novo Nordisk and Eli Lilly, in one of Europe's largest economies. For competing healthcare insurers and private supplemental insurance providers, a positive coverage ruling could accelerate policy design to differentiate on obesity management programs. German pharmaceutical distributors and hospital networks treating obesity-related comorbidities face a structural revenue shift if treatment becomes mainstream.

The policy trigger to watch is the German Federal Joint Committee's (G-BA) formal benefit-assessment ruling on GLP-1 drugs for obesity, which sets mandatory reimbursement criteria. If Germany approves GKV coverage, France and other EU markets often follow within 12-24 months, creating a cascading expansion of European addressable market. The macro variable is whether governments prioritise short-term fiscal discipline over long-term obesity-complication cost savings, a trade-off that currently divides European health ministries.

Synthesized from 3 sources.